Open Source Synthetic Biology: Problems and Solutions by Fitzpatrick, Ethan R
Seton Hall University
eRepository @ Seton Hall
Law School Student Scholarship Seton Hall Law
2013
Open Source Synthetic Biology: Problems and
Solutions
Ethan R. Fitzpatrick
Seton Hall Law
Follow this and additional works at: https://scholarship.shu.edu/student_scholarship
Recommended Citation
Fitzpatrick, Ethan R., "Open Source Synthetic Biology: Problems and Solutions" (2013). Law School Student Scholarship. 47.
https://scholarship.shu.edu/student_scholarship/47
 1 
 
Open Source Synthetic Biology: Problems and Solutions 
Ethan R. Fitzpatrick*  
 
 
 
I. Introduction 
 
 In May 2010, the J. Craig Venter Institute announced the creation of a simple bacterial 
cell entirely controlled by a chemically synthesized genome.
1
 The scientists started with the 
digital information of the organism’s genomic DNA sequence and chemically synthesized one 
nucleotide at a time, the full 1.08 million base pairs that made up the organisms genome.
2
  The 
synthetic genome was then inserted into a host bacterium that had its native DNA removed.
3
  
The resulting man-made bacterium was able to replicate itself using only the synthetic genome.
4
  
Advances in the ability to synthesize genome-length strands of DNA have coincided with a 
growing understanding of the functions of individual genes and gene networks.
5
  With the 
available knowledge of how whole genomes function and the technical capability of synthesizing 
whole genomes, it will be possible to digitally design novel organisms to perform some desired 
function and then manifest that synthetic organism in the real world.
6
  Creation of the first 
synthetic organism provided “a proof of principle for producing cells based on computer-
designed genome sequences.  DNA sequencing of a cellular genome allows storage of the 
                                                          
*J.D. Candidate, May 2013, Seton Hall University School of Law; Ph.D., University of Medicine and Dentistry of 
New Jersey, 2010; B.S. Rider University, 2002.  Thanks to Professor Jordan Paradise for her guidance, Becky 
Garibotto for her comments and encouragement, and Desiree Grace for her thorough editing and assitance. 
1
 D.G. Gibson et al., Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome, 329 SCIENCE 52 
(2010). 
2
 Id. 
3
 Id. 
4
 Id. 
5
 Matthias Heinemann & Sven Panke, Synthetic Biology—Putting Engineering Into Biology, 22 BIOINFORMATICS 
2790 (2006).  
6
 See Gibson et al., supra note 1. 
 2 
 
genetic instructions for life as a digital file.”7 “The approach we have developed should be 
applicable to the synthesis and transplantation of more novel genomes as genome design 
processes.”8   
   This ultimate goal of designing novel synthetic organisms using the technology of 
synthetic biology sounds like pure science fiction, but it is entirely possible and would have an 
enormous impact on biotechnology and medicine. Synthetic organisms might be designed to 
create new sources of food, fuel, and medicine that current technology is not capable of 
producing. Additionally, these benefits will arrive with incredible speed, efficiency, and cost 
effectiveness. Designing wholly novel synthetic organisms is still on the horizon, however, and 
presently scientists are left with a combination of older methods to innovate in the field of 
biotechnology, or more recently, the emerging technology of synthetic biology in its earliest 
phase.  In order to make the possibilities of synthetic biology a reality in the least amount of 
time, one organization—the BioBricks Foundation—is attempting to protect this emerging field 
from the potential stifling effects of DNA-patents by establishing an open source movement.
9
  
The hope is that an open-source synthetic biology commons would encourage innovation in 
ways similar to the wildly successful open source software movement.
10
  Towards that end, a 
similar open-source approach to synthetic biology might be useful.
11
  The world of synthetic 
biology, however, poses unique problems to the establishment of an open source movement.  
These problems include incentivizing entities to participate, maintaining openness once it is 
established, and creating useable biomedical products.     
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 Part II of this Comment provides an overview of the technology of synthetic biology and 
explains why it is important.  Part III introduces the current movement towards open source 
synthetic biology, as established by the BioBricks Foundation, and Part IV describes the past 
strategies used to establish and maintain other analogous open-source biotechnology movements.  
Three specific strategies are discussed: a copyright approach, a contract-based approach, and a 
patent-based approach to establish and maintain a commons. Part V then assesses whether these 
approaches to maintaining a synthetic biology commons are possible, and if so, what problems 
might be unique to synthetic biology.  Part VI then proposes a wholly novel strategy to advance 
the progress of synthetic biology.  This strategy uses an open-source/property-right hybrid 
approach, under the auspices of a standard setting organization, in order to overcome problems 
that cannot be addressed under the three previously described strategies.  The Comment then 
concludes. 
 
II. Synthetic Biology: What is it and Why is it? 
A.  Recombinant DNA technology laid the foundation for genetic engineering. 
 Deoxyribonucleic acid (DNA) is the molecule which encodes the instructions for life.
12
 
The DNA language uses four nucleotides—adenine, thymine, cytosine, and guanine—organized 
in specific sequences to compose the genes responsible for heritable traits.
13
  The DNA sequence 
of an organism gets copied with an extremely high fidelity, averaging only one nucleotide error 
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for every billion nucleotides copied.
14
  This DNA sequence is passed on to offspring, 
transmitting genetic information from generation to generation.
15
  
 Scientists have been tinkering with DNA since 1972, when Paul Berg, Stanley Cohen, 
and Hubert Boyer, discovered a way to cut and paste pieces of DNA together.
16
 This was 
followed by many further advances in manipulating sequences of DNA, such as the invention of 
the “polymerase chain reaction” (used to amplify pieces of DNA), rapid sequencing technology, 
and targeted gene replacement.
17
  Before the development of these technologies, the sheer size 
and chemical-repetitiveness of DNA made it one of the most difficult molecules to study and 
manipulate.
18
  The advent of the above methods, however, now makes DNA one of the easiest 
molecules to manipulate.
19
  Presently, the technology has reached a level of such sophistication 
that scientists routinely recombine the DNA sequences within a species (or even between 
species), resulting in novel DNA sequences that do not exist in nature.
20
  This “recombinant 
DNA technology” (rDNA technology) has had numerous applications as far reaching as 
medicine, research, and agriculture.
21
  Despite these advances, however, scientists have been 
limited by rDNA technology.
22
  Generally, rDNA techniques involve manipulating a small 
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number of genes and each modification involves a very time consuming procedure.
23
  This 
limitation, together with a very superficial understanding of how genes work alongside one 
another, has resulted in most scientific advances using rDNA technology involving the 
engineering of a single gene.
24
  For example, recombinant human insulin, which has almost 
entirely replaced insulin derived from animal sources,
25
 is synthesized by expressing a single 
human insulin gene in the bacteria E. Coli.
26
  In the specific case of human insulin production, 
manipulation of a single gene is sufficient to achieve the desired result; creating an alternative 
source of insulin for people with diabetes.
27
  In some situations, however, manipulating single 
genes is not sufficient and in those cases the emerging technology of synthetic biology is 
allowing scientists to move beyond the limitations imposed by recombinant DNA techniques. 
 
B. Defining the New Technology of Synthetic Biology  
 Defining synthetic biology is not easy.  There is no bright line that distinguishes the older 
rDNA technology from the new synthetic biology.
28
  The term has arisen in light of advanced 
techniques for chemically synthesizing sequences of DNA, along with a growing understanding 
of how multiple genes work in groups to form “gene networks” or “gene circuits.”29    Thus, it is 
not surprising that the term means something different depending on one’s technical background.  
                                                          
23
 See e.g., Bruce A. Roe et al., Protocols for Recombinant DNA Isolation, Cloning, and Sequencing, 
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Drew Endy, one of the pioneers of synthetic biology, states that for the biologist, the term means 
“the ability to design and construct synthetic biological system [to] provide a direct and 
compelling method for testing our current understanding . . . .”30  For the chemist, synthetic 
biology “is an extension of synthetic chemistry[:] the ability to create novel molecules and 
molecular systems [to allow] the development of useful diagnostic assays and drugs, expansion 
of genetically encoded functions, [and] study of the origins of life . . . .”31  For the group of 
people Endy terms “re-writers,” the term means that “the genomes encoding natural biological 
systems can be ‘re-written,’ producing engineered surrogates that might usefully supplant some 
natural biological systems.”32  And finally, for engineers, synthetic biology is an attempt “to 
combine a broad expansion of biotechnology applications with . . . an emphasis on the 
development of foundational technologies that make the design and construction of engineered 
biological systems easier.”33   
 For the purposes of this Comment, the technology of synthetic biology is summarized as 
follows: Advances in the ability to chemically synthesize sequences of DNA, plus a growing 
understanding of how genes function singularly and in groups, allowing scientists to treat genes 
as biological parts that they can use to engineer a living organism—much like an engineer would 
use various parts to build a car.  This Comment adopts this definition of synthetic biology 
because the technological capability of designing standardized biological parts is necessary for 
the establishment of open-source synthetic biology.
34
  The definition is largely drawn from 
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Endy’s engineering perspective of synthetic biology in order to stress the importance of 
composable biological parts that individuals can design and then contribute to a synthetic 
biology commons.  Also, this definition emphasizes that the difficulty or ease with which 
scientists can create biological parts will be an important factor in the success or failure of a 
synthetic biology commons.
35
    
 
C. Faster, Easier Genetic Engineering via Synthetic Biology 
 One of the underlying goals of synthetic biology is to make genetic engineering faster 
and easier.
36
  This goal can only be reached if standardized tools and methods are established 
that make genes and gene networks function predictably and reliably.  Unfortunately, current 
rDNA techniques largely lack any kind of standardization, which severely reduces the pace of 
technological innovation.
37
  An analogy might be building a car from scratch—starting with 
screws and a screw driver, finishing with a fully functional car.  An engineer with established 
tools and parts can build a car from scratch with little difficulty because the function of each part 
is known and standards are in place for parts to work together.  But imagine the challenge of 
building a car from scratch not knowing how each part works or whether individual parts can 
work together.  Without standard parts and tools, the builder would work by trial and error, 
                                                                                                                                                                                           
small.  With this in mind, I emphasize the development of discrete biological parts in my definition of synthetic 
biology. 
35
 See id.  Professor Opderbeck points out that rDNA technology poses some technical problems with respect to 
component “layers” in the context of open source biotechnology. For example, manipulating DNA requires 
specialized equipment and expertise. Advances in synthetic biology, however, might significantly lower this open 
source barrier. Specifically, advances in DNA synthesis methods have the potential to make manipulating DNA 
sequences easy, fast, cheap, and without formal training.  Standardization of biological parts may also fulfill the 
need for a common biotechnology platform.  Professor Opderbeck also notes that to establish open source 
biotechnology, there must exist social-psychological rewards and a community of contributors with authoritative 
voices.  While these two factors are outside the scope of this Comment, the BioBrick Foundation could arguably be 
in the initial stages of fulfilling these needs.  
36
 Reshma P. Shetty, Drew Endy, & Thomas F. Knight, Engneering BioBrick Vectors from BioBrick Parts, 2 
JOURNAL OF BIOLOGICAL ENGINEERING 1, 1 (2008), available at http://www.jbioleng.org/content/2/1/5 
37
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resulting in a significantly longer time to completion.  This problem is compounded in the 
context of a living organism—biological systems are far more complex than a car, and every 
biological part has the opportunity to interact with every other biological part.  Presently, all 
engineering of novel gene networks requires a significant amount of trial and error during 
development. For this reason, without standardized biological parts, the pace of innovation will 
be glacial.  
 To make this point, Endy uses the example of creating a biological oscillator.
38
  An 
electrical engineer could create several working ring oscillators in under an hour.
39
  In contrast, it 
took two of the world’s best biophysicists a year to make an analogous biological oscillator.40  
The difference is that electrical engineers have standard parts available to them that work 
predictably and reliably, while people working in the biological sciences do not.
41
  If synthetic 
biological techniques are used to make molecular biology more like an engineering discipline, it 
will rapidly increase the rate at which scientists create biotechnology-related products and 
therapies. 
 One area that would benefit from an increase in the pace of progress is in the field of 
medicine.  Recently, scientists have taken a synthetic biology approach to engineer biological 
systems as novel therapies in a pre-clinical setting.
42
  For example, scientists engineered a 
bacteriophage (a virus that infects bacterium) that can destroy bacterial biofilms resistant to 
antibiotics.
43
 Another example is a bacteria engineered to invade cancer cells in a solid tumor.
44
  
                                                          
38
  Warren C. Ruder, Ting Lu, & James J. Collins, Synthetic Biology Moving into the Clinic, 333 SCIENCE 1248, 
1249 (2011).  
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A synthetic organism is even being developed to modify the “human microbiome,” the 
endogenous ecosystem of bacteria found in all healthy people which is required for normal 
physiology.
45
  Scientists are engineering the microbiome bacterium to live in the human gut with 
the ability to prevent the secretion of toxins from cholera.
46
  Other bacteria have been engineered 
to secrete various factors to treat diabetes or HIV.
47
  Scientists may even be able to engineer a 
laboratory mosquito that is resistant to hosting malaria and that would be able to pass the 
resistance trait into the natural population of mosquitoes.
48
  
 All of these advances were the result of manipulating genomes by removing and/or 
adding various parts to alter biological pathways.
49
  These first few attempts at controlling the 
behavior of an organism with synthetic biology techniques—by manipulating a relatively modest 
number of genes—is useful for animal studies.50  But in order to be possible in human beings, it 
“may be necessary to identify entirely new modules and components from endogenous networks 
as well as to synthesize and characterize diverse component libraries.”51  In order to support 
human application, the degree of control over the behavior of synthetic organisms will have to 
increase dramatically.
52
  There is a strong motivation to advance the technology of synthetic 
biology as fast as possible given the immense promise in the field of medicine.  The quicker that 
scientists make advances, the sooner they will develop wholly novel therapies to treat human 
disease.  
 
                                                          
45
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III. Advancing Genetic Engineering Through Open-Source Synthetic Biology 
 The benefits of synthetic biology’s engineering principles are clear: faster, easier, and 
more novel solutions to the world’s biologically addressable problems.  But the question 
remains: Once standard biological parts are created, how should they be used in order to foster 
innovation?  Currently, gene patents dominate the biotechnology landscape.
53
  Literally tens of 
thousands of human genes are patented by various companies who solely own the patent rights to 
use them.
54
  Many commentators have posited that these patent rights slow the pace of progress 
dramatically.
55
  Emerging technologies are, by their very nature, especially vulnerable to broad 
patents that suppress innovation.
56
  Some commentators fear that “foundational patents” (also 
known as “upstream patents”), which are patents that cover an essential aspect of a technology 
and are usually very broad in scope, will stifle the development of synthetic biology, along with 
all of its potential benefits to mankind.
57
  This is because the technology that a foundational 
patent covers is necessarily incorporated into any downstream research or resulting product.
58
  
 One response addressing the potential threat of patents inhibiting synthetic biology 
innovation is to establish a synthetic biology commons where standard biological parts are made 
freely available to all.
59
  Once foundational biological parts are made publicly available in such a 
commons, individual entities would not have the right to patent them.
60
  Furthermore, some 
                                                          
53
 See Sam Kean, The Human Genome (Patent) Project, 331 SCIENCE 530 (2011). 
54
 Id. at 531. 
55
 See Micheal A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical 
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60
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commentators have argued that this strategy has the added benefit of encouraging innovation.
61
 
This “open-source” approach to synthetic biology is analogous to the open-source software 
movement which was wildly successful and resulted in the creation of countless computer 
applications including the Linux operating system.
62
  
 The following subsections examine what it means to be “open-source” and how those 
open-source principles are currently applied to the emerging technology of synthetic biology.  
One organization in particular, the BioBricks Foundation, has been established in an initial 
attempt to launch an open-source community.
63
  Part III. A will describe what it means to be 
“open-source,” and the terms used to maintain openness in the context of computer software.  
Part III. B will discuss the open-source strategy of the BioBricks Foundation, and Part III. C will 
consider the problems associated with maintaining openness. 
 
A. Open Source 
 The term “open source” has become strongly associated with computer software code 
that is made freely available for individual use and modification.
64
  The principles that open-
source computer programmers established, however, are applicable to other technologies, 
including synthetic biology.  The Open Source Initiative (OSI), which uses the term in the 
software context, defines “open source” as terms of distribution that comply with specific 
criteria.
65
  The OSI uses ten different terms of distribution, all of them written with software 
                                                          
61
 Andrew W. Torrance, Synthesizing Law For Synthetic Biology, 11 MINN. J. L. SCI. & TECH. 629, 650–51 (2010). 
62
 Id. at 654. 
63
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2012). 
64
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65
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development in mind.
66
  But each term can be applied to other technologies where non-rivalrous 
information
67
 is being freely distributed, including the technology of synthetic biology.  The 
most important OSI requirements with respect to maintaining openness are: allowing free 
redistribution, allowing derived works, and allowing a distribution of licenses.
68
  The free 
redistribution term requires that a “license shall not restrict any party from selling or giving away 
the software as a component of an aggregate software distribution containing programs from 
several different sources.  The license shall not require a royalty or other fee for such sale.”69  
The derived-works term states that “the license must allow modifications and derived works, and 
must allow them to be distributed under the same terms as the license of the original software.”70  
And the distribution of license term states that “the rights attached to the program must apply to 
all to whom the program is redistributed without the need for execution of an additional license 
by those parties.”71  Importantly, software developers writing computer code have the intellectual 
property rights—in copyright law—that are required to impose these terms on others who would 
use their works.
72
  The BioBricks Foundation is a pioneering institution that is actively seeking 
to establish an open source biotechnology community by applying open source principles to the 
emerging field of synthetic biology.
73
   
                                                          
66
 Id. 
67
 See Opderbeck, supra note 34, at 207–08. (“[I]nformation commons theorists hold that information is non-
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68
 Open Source Definition, supra note 64. 
69
 Id.  
70
 Id. 
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 Id. 
72
 17 U.S.C. § 101 (Literary works include words, numbers, or other indicia, regardless of the nature of its 
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73
 The BioBricks Foundation works to ensure that the engineering of biology is conducted in an open and ethical 
manner to benefit all people and the planet, BIOBRICKS.ORG, http://biobricks.org (last visited Feb. 11, 2012) (“We 
are dedicated to advancing synthetic biology to benefit all people and the planet. To achieve this, we must make 
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B. BioBricks Foundation 
 The BioBricks Foundation is an organization established to advance the field of synthetic 
biology “by ensuring that the fundamental building blocks of synthetic biology are freely 
available for open innovation.”74  Toward that end, the BioBricks Foundation has established the 
first synthetic biology commons where various DNA “parts” are made freely available for public 
use, applying open-source software principles.
75
   
 With the goal of openness in mind, the foundation has created User/Contributor 
contracts—collectively titled “BioBricks Public Agreement”—to promote the use and innovation 
of BioBricks parts.
76
 The terms of the BioBricks Public Agreement are meant to ameliorate the 
threat of patent rights over BioBricks parts in an attempt to promote their open and free use.
77
  
The main goal of this open strategy is to “accelerate the pace of innovation, collapse 
development timelines and speed time-to-market of inventive synthetic biology-based solutions 
while fostering the ethical use of the technology.”78 The contracts contain some terms that are 
analogous to OSI open source terms of distribution.
79
 The BioBricks Public Agreement is 
described as “a scalable contract among parties”—a contract “between one person who wants to 
make a genetically encoded function free to use and someone who wants to use it freely.”80  
                                                                                                                                                                                           
fundamental building blocks of synthetic biology are freely available for open innovation; by creating community, 
common values and shared standards; and by promoting biotechnology for all constructive interests.”). 
74
 Id. 
75
 FAQ, BIOBRICKS.ORG, http://biobricks.org/faq/ (last visited Feb. 11, 2012). 
76
 Id. 
77
 Id. 
78
 About the BioBricks Foundation, BIOBRICKS.ORG, http://biobricks.org/about-foundation/ (last visited Feb. 12, 
2012). 
79
 Compare The BioBrick Contributor Agreement, BIOBRICKS.ORG, http://biobricks.org/wp-content/themes/bbf/bpa-
sample.php (last visited Feb. 12, 2012) with Open Source Definition, supra note 64. 
80
 Frequently Asked Questions, BIOBRICKS.ORG, http://biobricks.org/bpa/faq/ (last visited Feb. 11, 2012). 
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There are two distinct types of contract—one for the “Contributor” and one for the “User.”81  
The Contributor is the person making the biological part available, while the User is the person 
using the part that the contributor provided.
82
  The Contributor contract states that a Contributor 
of a BioBricks part makes “an irrevocable promise not to assert any existing or future intellectual 
property rights over the something against the other party to the contract.”83  Furthermore, the 
Contributor of a BioBricks part must disclose the existence of any intellectual property rights to 
the part held either by the Contributor or by a third party.
84
  The User contract states that a User 
promises to “provide attribution to the contributor, where requested, and to respect biological 
safety practices and applicable laws.”85    
 Some commentators have noted that the BioBricks Public Agreement sets forth more 
than the mere terms of a license intended to prevent disputes over ownership rights.
86
  Rather, the 
terms of the BioBrick Agreement are “an initial effort to draft a legal constitution to guide the 
beneficial development of the field of synthetic biology.”87 
 Importantly, the BioBricks Public Agreement does not include some provisions included 
in the OSI terms of distribution.
88
  For example, the BioBricks Public Agreement does not 
contain any provision requiring a grantback of any derived works.
89
  As discussed in the 
following section, the absence of some OSI terms of distribution will create significant 
challenges to maintaining an open-source synthetic biology movement.  
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C. Challenges Maintaining the BioBricks Commons 
 There are several significant threats to the openness of the BioBrick commons.  Three of 
these challenges will be discussed in this section specifically.  The first challenge is derivation: 
getting contributors to donate derived work back to the BioBricks Foundation and not assert any 
intellectual property rights. The second challenge is motivation: incentivizing individuals or 
entities that currently hold patent rights of biological parts to donate them to the BioBricks 
Foundation in the first place. The third challenge is the absence of an end product: the open 
source synthetic biology community will not be able to realize the potential of novel medically 
relevant inventions on its own. The first two challenges stem from the terms of the BioBricks 
Public Agreement, while the third challenge is inherent in biomedically relevant research.  Each 
challenge will be considered in turn. 
 i. Derivation 
    One of the goals of the BioBricks Foundation open-source community is to foster the 
creation of novel biological parts by derivation from the parts currently found in the registry.
90
 
But the absence of terms in the BioBricks Public Agreement that require all derived works to be 
donated back to the BioBricks Foundation creates a challenge.  Unless they are the inventor of 
the biological part, a User would be barred from asserting any intellectual property rights over 
any individual biological part once contributed to the BioBricks Foundation.
91
 But there is 
nothing stopping a user from asserting intellectual property rights over a different biological part 
that is derived from BioBrick parts.  In other words, if a person has signed the BioBricks User 
Agreement and, in using the BioBrick parts, creates a new part with a novel function, there is 
                                                          
90
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nothing stopping that person from patenting that novel part and asserting intellectual property 
rights over it.  In fact, the User Agreement specifically states that there is no requirement to give 
any novel materials or applications back to the foundation.
92
  The BioBricks Foundation makes 
perfectly clear that “[n]ovel materials and applications produced using BPA-contributed parts 
may be considered for protection via conventional property rights.”93  As a result, the BioBricks 
User Agreement is fundamentally different from the traditional open source agreement, which 
requires any derived works to be licensed back under the same terms as the original.
94
  Without a 
reciprocal licensing mechanism in place to ensure that novel biological parts will continue to be 
derived from past work of users, maintaining a cycle of innovation by participants in the 
synthetic biology commons may be challenging.    
 ii. Motivation 
 A second problem, arguably equally as important as the first, is that there is no clear 
reason for a person with intellectual property rights over a part to surrender those rights and 
donate the part to the BioBricks Foundation.  Arguably, the only motivation is to make a 
philanthropic gesture.  Professor Andrew Torrance has noted that “it is not obvious what 
incentives contributors would have to contribute their BioBricks, especially if they must 
relinquish any intellectual property rights they may have in order to do so.”95   
 iii. End Product 
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93
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94
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 There is a third problem that is unique to synthetic biology as applied to the field of 
medicine—there is no immediately usable end product.96  Other open-source movements, such as 
the open source software movement, were wildly successful partly due to the fact that a working 
product resulted from the aggregate work of many individuals.  For example, the Linux operating 
system, developed over many years by thousands of people, is downloaded and used by anyone 
in the world after all the effort has been put forth to make it.
97
  That is not always the case in the 
world of biotechnology.
98
  If members of the BioBricks Foundation were to engineer a microbe 
to be a medical therapy, the end product could not be immediately used because introduction of 
the product requires lengthy, and extremely costly, clinical trials as a drug, biologic, or medical 
device.
99
  It is likely that an entire community of BioBricks members would not have the 
knowledge or resources available to undergo this task.    
 Thus, there are several problems to overcome in establishing a viable open source 
synthetic biology movement. The first is getting people/corporations to make their derived 
works, which may be very valuable, available for further use by the public free of charge.  The 
second is getting people/corporations with intellectual property rights to contribute parts. The 
third, in the context of designing a medical therapy, is getting a synthetic biology product 
through clinical trial so that it will actually be used to benefit the world. 
 The first two problems have been addressed in the context of other open-source 
movements involving emerging technologies under the threat of patents stifling progress.
100
  In 
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the context of those specific technologies, several different strategies have been devised to 
maintain openness.    Parts IV and V will address three strategies that have been applied to other 
technologies that can potentially be applied to maintaining open source synthetic biology.  Each 
of the following strategies has been evaluated previously in the context of a specific technology 
and each has been successful in maintaining some degree of openness.
101
  Part IV will introduce 
these previously proposed strategies.  Part V will answer the question of whether any of the 
proposed strategies would be applicable to a synthetic biology commons, and if so, whether it 
would be successful. The three strategies to be evaluated are the Copyright Open-Source 
approach, the HapMap License approach, and the BIOS patent approach. 
 
IV. Previously Proposed Open Source Strategies 
A. Copyright Open-Source Approach 
 Currently, copyright protection for sequences of DNA is not available.
102
  But if 
sequences of DNA could be protected under Copyright Law, then it would be relatively 
straightforward to implement open-source synthetic biology in an analogous fashion to open-
source software.
103
  A license to use the DNA “work” would include provisions that require the 
user to give back to the commons any derivative works.
104
 The General Public License (GPL)
105
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that has been commonly used in open source software could be easily adapted to cover DNA
106
 
and would have the same open source effect—novel sequences of DNA or novel combinations of 
established sequences that have been derived from previous work covered by the GPL would 
remain available to the public. 
  Several commentators have suggested that it is feasible for sequences of DNA to be 
covered by copyright law.
107
  Some have even suggested that this approach could be used to 
establish open source synthetic biology.
108
 These scholars have reasoned that DNA sequences 
are very similar to computer software code because both involve a set of instructions that are 
read, then executed, and any unique issues that might arise in the context of synthetic biology 
could be absorbed with a relatively small incremental change to Copyright Law.
109
   
 For example, Dr. Christopher Holman makes the case that engineered DNA should be 
protected by Copyright Law.
110
 He argues that “the major doctrinal leap occurred thirty years 
ago when copyright protection was recognized for computer programs. In view of the close 
analogy between software and engineered DNA, the further extension to encompass engineered 
genetic sequences is a relatively modest incremental expansion.”111  Dr. Holman argues that 
engineered sequences of DNA and computer code both are essentially sets of instructions that are 
read and executed by hardware.
112
  For computer code, the hardware is the group of computer 
components itself; for DNA sequences, the hardware is the group of proteins, carbohydrates, and 
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fatty acids that make up a living cell.
113
  Further bolstering the Copyright argument, advances in 
biotechnology have made possible a certain level of creativity in generating DNA sequences.
114
  
This is important because the Supreme Court, in Feist Publications, Inc. v. Rural Telephone 
Service Co. Inc.,
115
 established a minimum threshold for a work to be covered by Copyright 
Law—the work must contain “a modicum of creativity.”116  This is a relatively low threshold 
that could be easily met even with the current state of synthetic biology because the current state 
of the technology allows for the creation of DNA sequences that are different—at least 
modestly—from what exists in nature.117  Additionally, the Supreme Court has consistently 
interpreted the Copyright Clause of the constitution broadly.
118
  The term “writing” has not been 
taken literally—photographs, art, motion pictures, and sounds have all been considered 
“writings.”119  Thus, there is good reason to believe that a molecule of DNA could be considered 
a “writing” and therefore could receive copyright protection.    
 Andrew Torrance makes a similar argument, but suggests that instead of only thinking 
about DNA sequences as being analogous to computer software, DNA might even be thought of 
as an actual form of computer software.
120
  This is especially true in the field of synthetic 
biology, where in the future a heightened degree of programmability will allow for a potentially 
limitless amount of creativity.
121
  This is seemingly equivalent to the freedom of a computer 
programmer to create any form of program, constrained only by the computer language and 
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hardware itself.  Indeed, Torrance even notes that one of the “goals of synthetic biology is to 
engineer cells and genes to become ever more like computers and computer software.”122  If this 
approach is assumed, then DNA is already covered by Copyright and no adaptation of law need 
be made at all in order to protect sequences of DNA.  
 
B.  HapMap Licensing Approach 
 Some open-source movements use a contract-based license to create an information 
commons in the realm of biotechnology and have been relatively successful.
123
  One in 
particular, the International HapMap Project, was a joint public-private venture to map genetic 
variation among the world’s human population.124  The stated goal of the HapMap project was to 
“help researchers find genes associated with human disease and response to pharmaceuticals.”125 
The HapMap Project originally created a data access policy that was meant to “avoid the filing of 
intellectual property claims that would impede other users access to the data.”126  Due to the 
success of open distribution, in 2004, approximately two years after the HapMap project had 
started distributing haplotype data, the HapMap Consortium decided that its data access policy 
was no longer required because enough data on human genetic variation was published that any 
patents derived from HapMap data would be considered obvious.
127
  Since then, all access to 
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HapMap haplotype data is freely accessible to anyone without having to sign a license 
agreement.
128
 
 The data-access policy that the HapMap Consortium formerly used included a licensing 
agreement that a user had to sign before gaining access to haplotype data.
129
  This mandatory 
licensing agreement stated that “you will have to agree to a single condition—that you will not 
restrict further use of the individual genotypes, i.e. take any action that would in any way restrict 
the access of others to the data produced by the Project.”130  The licensing agreement also 
prohibited distribution of data from the HapMap project to parties that had not accepted the 
terms of the license.
131
  This provision addressed the possibility that a party who signed the 
license could simply give the haplotype data to a third party who had not signed it and was not 
bound by its terms.  
 
C.  The BiOS patent approach  
 Another past strategy to establish and maintain openness is a patent-based approach, 
which the Biological Innovation for Open Society (BiOS) utilized.
132
  The BiOS initiative was 
created “in response to inequities in food security, nutrition, health, natural resource management 
and energy.”133  BiOS currently holds the intellectual property rights to several technologies 
relevant to food production.
134
  For example, BiOS holds patents on several plant technologies, 
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including plant-gene transfer methods, generation of plant-gene fusions, and methods for 
genotyping genetically engineered plants.
135
  Because BiOS holds the patent rights associated 
with those technologies, it can make those technologies freely available to anyone who wishes to 
use them if they agree to the terms of the BiOS license.
136
  The mandatory license requires users 
to “grant back any improvements in the core technology and to make such improvements freely 
available to all others on the same terms that BiOS provided for the original core technology.”137 
 Some academics, such as Professor Robin Feldman, suggest that this grantback 
requirement may implicate patent misuse.
138
 Patent misuse occurs when the patent holder 
attempts to expand the physical or temporal scope of a patent monopoly beyond what was 
originally granted in the patent.
139
  “To the extent that a patent holder uses its rights to restrict the 
disposition of inventions not covered by the grant, the patent holder may be engaging in behavior 
that extends the scope of the patent grant and thereby may be subject to a claim of misuse.”140  
But by Professor Feldman’s reasoning, it is highly unlikely that BiOS would actually find itself 
in court under a theory of patent misuse because the BiOS grantback requirement is not 
inconsistent with patent policy and any anti-competitive effects are outweighed by the pro-
competitive benefits.
141
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V.  Application of Past Strategies to Synthetic Biology 
 In light of the previous open-source strategies described in Part IV, the question is 
whether any of the copyright, license, or patent based approaches to maintaining openness would 
work in the context of synthetic biology.  The following section applies these previous strategies 
to synthetic biology and assesses whether any of them can be used to maintain an open source 
synthetic biology movement.  Application of these strategies to the technology of synthetic 
biology reveals that none of them are ideally suited to maintaining openness.  The copyright 
approach and patent based approach are especially unlikely to be useful because of recent federal 
circuit decisions and prohibitive expense, respectively.  While the license based approach can be 
applied to synthetic biology, it has several flaws that must be overcome in order to sustain an 
open source synthetic biology movement.   
   
A.  Copyright Availability For Open Source Synthetic Biology 
 The Copyright approach to open-source synthetic biology is not without problems 
because the applicability of copyright to sequences of DNA is untested. While various scholars 
have made several compelling arguments that DNA sequences should be covered by Copyright 
Law, there is currently no indication that the U.S. Copyright Office or Congress would approve 
the use of Copyright Law to protect DNA sequences.
142
  Also, Andrew Torrance, Sapna Kumar 
and Arti Rai have pointed out that the Copyright approach may not work for DNA sequences that 
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already exist in nature.
143
  Indeed, Copyright is intended to prevent verbatim copying of a 
writing, whether it be in the form of computer software or DNA sequence.
144
  Thus, no naturally-
occurring sequences of DNA could be protected under a Copyright.
145
  While designing novel 
DNA sequences that do not exist in nature may become commonplace in the future with 
synthetic biology, the current state of the technology largely involves previously existing genetic 
code.
146
  For example, the vast majority of BioBrick parts made available in the registry are 
sequences of DNA taken directly from naturally-occurring organisms.
147
 
 The Federal Circuit’s view on intellectual property rights of DNA poses another high 
hurdle for DNA Copyright protection.
148
 While there is no direct indication that the Federal 
Circuit would approve or disapprove the use of Copyright to protect sequences of DNA, there is 
some indirect indication that it would not be receptive to Copyright protection for sequences of 
DNA, even if the sequences were completely novel.
149
  The Association for Molecular Pathology 
et al. v. United States Patent and Trademark Office et al. (Myriad gene patent case) offers some 
insight into how the Federal Circuit views intellectual property rights surrounding sequences of 
DNA.
150
  While patents and copyrights are distinct bodies of intellectual property law, the court’s 
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reasoning in the gene patent cases may be an indication of future unwillingness to allow 
Copyright protection for DNA.
151
  
   On July 29, 2011, a three-Judge panel in the Federal Circuit handed down three separate 
opinions in the controversial Myriad gene patent case.
152
 The original decision on appeal, 
authored by Judge Sweet from the Southern District of New York, held that a composition of 
isolated genomic DNA was not patentable subject matter.
153  
Judge Sweet seized the idea that 
DNA is a carrier of information and that this property gives it utility.
154
 Any isolated DNA 
containing the same sequence information of native DNA is therefore a product of nature and 
unpatentable. 
155 
 Two out of the three judges on the Federal Circuit panel, completely rejected 
Judge Sweet’s reasoning.156  Judge Lourie held that focusing on the “information content 
contained in . . . DNA’s nucleotide sequence” ignores the distinctive characteristics that isolated 
DNA molecules have when compared to what exists in nature.
157
  Judge Lourie further stated 
that when determining patent eligibility of DNA, the “informational content is irrelevant.”158 
Judge Moore concurred with Judge Lourie on the issue of patent eligibility of isolated genomic 
DNA sequences, but wrote separately to emphasize the differences in utility of isolated DNA 
when compared to native DNA.
159
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 If the majority of the Federal Circuit panel had agreed with Judge Sweet and emphasized 
the information carrying qualities of DNA, a parallel argument could be made that, while not 
patentable, sequences of DNA could be protected by copyright law.  If the informational aspect 
of a molecule of DNA was emphasized, then one could reasonably argue that the genetic 
information is simply read and executed by other cellular machinery in an analogous fashion to a 
computer reading and executing software instructions.
160
 Thus, if courts emphasize the 
informational aspect of DNA, then there would exist some judicial reasoning in support of the 
conclusions of Hollman and Torrance that Copyright should be applicable to sequences of DNA, 
much like Copyright is applicable to computer software.
161
    
 Since the majority of panel judges rejected viewing DNA as, first and foremost, a carrier 
of information, the arguments for the copyright protection of DNA sequences would not find 
support in the reasoning of the Federal Circuit.  Furthermore, with the Federal Circuit’s decision 
in the Myriad gene patent case, patents are clearly available for protection of sequences of 
DNA.
162
  As Kumar and Rai have noted, “courts and Congress might be reluctant to layer on an 
entirely new kind of property right, for fear that such rights would hurt rather than help 
innovation.”163  Thus, despite the sound arguments for why DNA should be protected under 
copyright law, it is unlikely that the Federal Circuit would actually support its use in that context. 
 The intellectual property rights available to sequences of DNA may change in the future.  
The Ass’n for Molecular Pathology et al. appealed the Federal Circuit’s Myriad gene patent case 
decision to the Supreme Court, which remanded the case to the Federal Circuit for consideration 
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in light of the Supreme Court’s decision in Mayo Collaborative Services v. Prometheus 
Laboratories.
164
  If the Supreme Court eventually takes the case and upholds the Federal Circuit 
majority, then the applicability of copyright protection to sequences of DNA will remain 
unlikely.  But if the Supreme Court were to agree with Judge Sweet, and emphasize the 
information-carrying properties of DNA sequences, it could effectively close the door on 
genomic DNA patents and open the door to genomic DNA copyrights.     
 
B. Application of HapMap Strategy to the BioBrick Public Agreement 
 Application of a HapMap license approach to maintaining an open source synthetic 
biology movement is possible, but brings with it issues associated with third-parties not in privity 
of contract and issues of enforcement.  The HapMap Licensing terms, which were relatively 
successful in establishing the open use of haplotype data, have some similarities to the current 
BioBricks Public Agreement.
165
  Both agreements contain terms that prohibit placing restrictions 
on the information/part that has been made available.
166
  Importantly, this strategy does not 
require any intellectual property right to bind the signing party to the terms of the license.
167
   
Kumar and Rai note that “this contractual alternative does not require an underlying property 
right.  Instead, the contract simply imposes conditions as part of the price of access.”168   
Furthermore, the online nature of a license-based strategy requires that the agreed upon web-
based contract be enforceable.  Donna Gitter has noted that “courts generally enforce clickwrap 
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agreements provided the licensee ‘receive[s] notice of the license terms before buying or using’ . 
. . ‘and has the ability to return . . . if he does not agree with the terms . . . ’”169  Since the 
HapMap user agreement was deemed to fulfilled these threshold requirements for enforceability, 
the similar click-wrap nature of the BioBricks agreement would likely fulfill these threshold 
requirements as well.  There are, however, several issues that still must be overcome.  
 i. Third-Party Problems 
 Third parties not in privity of contract who gain access to BioBricks parts, however, will 
create problems that must be overcome. Commentators have pointed out that a licensing 
agreement would not prevent third parties, who have gained access without signing, from 
violating its terms.
170
  Gitter points out that the HapMap license “does not bind third parties who 
obtain and use HapMap data without downloading it from the HapMap website and who 
therefore are not in privity of contract . . .”171  A similar problem exists in the case of the 
BioBricks Public Agreement; any third party that obtains a BioBrick part without agreeing to the 
license would not be bound by its terms.
172
  The HapMap approach to overcoming this problem 
was to include terms in the user agreement that specifically prohibited dissemination of HapMap 
data to parties that have not signed an agreement.
173
  Kumar and Rai suggest that this indicates 
one of the difficulties when using contract law to maintain openness: “the comparative weakness 
of the contractual restraints paradoxically requires extremely broad restrictions on 
dissemination.”174  A similar contradiction would exist in the context of the synthetic biology 
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commons: the openness of the BioBricks parts could only be protected from third parties by 
severely restricting the openness of the BioBricks parts.  
 The BioBricks Foundation has not, however, implemented this type of third-party 
restriction.
175
   In contrast, the BioBricks Foundation’s ethos of openness suggests that it would 
actually want to encourage the free distribution of BioBricks parts to third parties in hopes of a 
third-party eventually making a donation back to the foundation.
176
  Thus, any third-party issues 
that existed in the context of the HapMap project will likely be amplified greatly in the context 
of the BioBrick Foundation, due to the absence of dissemination restrictions.  
 ii. Enforcement Problems 
 In addition to the problems associated with third parties violating the terms of a license, 
there may also be enforcement problems even with parties who have agreed to the license terms. 
For example, a party may agree to a license that relinquishes any intellectual property rights, but 
that party may later ignore the provision and file for a patent anyway.   Under this circumstance, 
there is no reason to believe that the patent would be void. As Professor David Opderbeck has 
noted, “[n]othing in the Patent Act would suggest that a patent could be invalidated because 
some of the underlying data was derived from a database in violation of the database’s terms of 
use.  Thus it is unlikely that the [license] provides any meaningful remedy once a patent has been 
filed.”177  In terms of the BioBrick Public Agreement, an individual could fail to disclose the 
existence of a pending patent on a biological part, but the resulting patent would not be 
invalidated due to this violation.
178
  Thus, users may disregard the terms of the BioBricks Public 
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Agreement, which are meant to maintain openness, without any real recourse for the BioBricks 
Foundation.
179
  
 There are further issues that arise if the Foundation decided to enforce the terms of the 
BioBricks Agreement in court.  Gitter notes that bringing suit against all parties who violate the 
user agreement would “create a significant financial and administrative strain upon the nonprofit 
research group, which must focus its efforts on pursuing research as opposed to enforcing its data 
access policy.”180  This certainly applies to the BioBrick Foundation, which is also a non-profit 
organization and has limited financial resources.  Additionally, the area of biotechnology is very 
much an international enterprise, and there may be no remedy against people who violate the 
terms of the BioBricks Agreement in other countries.
181
 As Gitter states, “[i]f the user happens to 
be located in a nation that does not enforce clickwrap licenses, then that user might not face legal 
liability for violating the . . . license.”182 
 
C. Application of BIOS Approach to BioBricks 
 There are several problems with attempting to maintain the synthetic biology commons 
using a patent-based strategy.  First, for this strategy to work, BioBricks would have to hold 
either a few broad foundational patents or a patent on each individual part in the collection.  Both 
of these options pose problems.  
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 Unlike the BiOS Initiative, currently the BioBricks Foundation does not hold the patent 
rights to any broad foundational patents.
183
  While a few broad foundational patents might be 
successfully used to maintain a commons, the difficulty with this approach would be to “identify 
an area of inventive territory that was quite broad but nonetheless not suggested either by prior 
broad patents or by information already in the public domain.”184  Considering the existence of 
several issued broad foundational patents, it is not likely that the BioBricks Foundation would be 
successful if it were to proceed with this approach. 
 The alternative is to obtain a very narrow patent on each BioBricks part currently in the 
registry.  This strategy would not only require the BioBricks Foundation to patent each part for 
which it is the inventor, it would also require each individual “inventor” who donates his or her  
part to the Foundation to obtain a patent as well.  This is not practically possible.  Obtaining a 
patent on a sequence of DNA, or any other structure or method, could cost tens of thousands of 
dollars each.
185
  The BioBrick registry currently holds thousands of BioBrick parts.
186
  Thus, the 
aggregate cost of maintaining a synthetic biology commons by patenting each individual part 
would easily be in the tens of millions of dollars.  This is a prohibitively large amount even for a 
large for-profit corporation and simply is not possible for the BioBrick Foundation.  
 
                                                          
183
 Several members of the BioBricks Board of Directors hold patents as individuals, but there is no indication that 
the Foundation itself holds any patents. See e.g., Board of Directors, BIOBRICKS.ORG, http://biobricks.org/about-
foundation/board-of-directors/ (Tom Knight, one of the founding members of BioBricks, holds over 30 patents). 
184
 Kumar & Rai supra note 57, at 1765. 
185
 The Cost of Obtaining a Patent in the US, IPWATCHDOG.COM, http://www.ipwatchdog.com/2011/01/28/the-cost-
of-obtaining-patent/id=14668/ (last visited Feb. 12, 2012) (Even the simplest technologies costs approximately 
$5,000-7,000 in attorney’s fees to obtain a patent, while more complicated technologies can cost in excess of 
$15,000).   
186
 There is no official count of the available BioBricks parts, but by simply browsing the registry, it is clear that 
there are many thousands of parts. Registry of Standard Biological Parts, PARTSREGISTRY.ORG, 
http://partsregistry.org/Main_Page (last visited Apr. 6, 2012). 
 33 
 
VI. A standard setting organization (SSO) strategy for establishing, maintaining, and using the 
end products of the synthetic biology commons 
 Part IV of this Comment introduced various strategies that have been used in the past for 
maintaining openness in different technological areas.
187
  Part V then applied those strategies to 
the technology of synthetic biology, concluding that a copyright- or patent-based approach is not 
possible and a license approach is less than ideal.
188
  Each of the previous strategies discussed to 
this point only address the problem of getting derived works of synthetic biology donated back to 
an open source community.  The problem of motivating patent holders to donate biological parts 
in the first place and the problem of getting biomedical end products into the clinic have not been 
addressed.  The following subsections lay out a novel strategy that may be able to tackle 
problems of maintaining openness while at the same time incentivizing donations and creating 
opportunities for realizing biomedical breakthroughs. This strategy involves establishing a 
synthetic biology standard setting organization (SSO). 
 
A. Standard Setting Organizations (SSO) 
 An SSO, also known as standard setting consortia, can consist of “anything from a loose, 
unincorporated affiliation of companies, to an incorporated entity with offices, marketing, 
technical and administrative staff and a multi-million dollar budget.”189  The goal of this type of 
organization is to set standards that are widely adopted throughout an industry in order to enable 
innovation of a business-service or product.
190
  The importance of standard setting cannot be 
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overstated.  Standards are found everywhere in our daily life.  The classic example is an 
electrical plug and socket
191—people in the United States can go to any store in the country and 
purchase any tool or device that requires power and be confident that they will be able to go 
home and the plug will fit.  Both the plug on the device and the electrical socket in the home are 
guaranteed to work together because a standard has been adopted.  Furthermore, “[o]rdinary 
products like printer cartridges and tires come in standardized sizes and specifications, which 
fosters choice and competition in the supply of replacement parts.”192  Thus, standards have the 
beneficial effects of promoting efficiency of innovation as well as competition in a marketplace. 
 Standards can be broadly classified into three groups: de facto standards, private 
standards, and government standards.
193
  De facto standards arise naturally in a market place 
when users adopt a standard to the exclusion of any competition.
194
  Government standards, in 
contrast, are promoted and enforced by a government entity—for example, the U.S. government 
selected a uniform standard for High Definition television in the 1990’s.195  Finally, private 
standards are adopted voluntarily by members of an industry, usually after the formation of a 
private SSO.
196
  Joining a private SSO is completely voluntary, “some flourish, while others 
enjoy only middling success, and some fail to gain traction at all.”197 
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 At the core of an SSO is the establishment of policies to deal with intellectual property 
rights, namely patents.
198
  To accomplish this, each SSO establishes a set of rules addressing the 
intellectual property rights of members who have joined.
199
  Two particularly important issues 
covered in the SSO rules are “whether and when patent claims must be disclosed” and the 
reasonable and nondiscriminatory (“RAND”) terms by which a member will license patent rights 
to other members.
200
  The RAND terms of a private SSO could possibly be designed to address 
the problems of maintaining open-source synthetic biology.   
 
B. A Standard Setting Organization Could Address the Problems of Maintaining Open Source 
Synthetic Biology 
 The establishment of a private standard setting organization might address the problem of 
incentivizing donation of patented biological parts by creating a medium through which the part 
could be used by an open source community while at the same time protecting the intellectual 
property rights of the donor.  An SSO might address issues involved with using a license to get 
derivative biological parts donated back to an open source community.  Finally, an SSO could 
foster collaboration between an open source synthetic biology community and private entities in 
order to introduce synthetic biology products into the clinic.   
 i.  Motivating Donation of Biological Parts 
 An SSO could overcome the problem of motivation by generating future value of a 
patented biological part, while at the same time protecting the intellectual property rights of the 
donor.  In some situations donation of parts might be made freely.  There is evidence that entities 
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holding patent rights over certain technologies would be willing to allow an open source 
community to use those technologies free of charge.  For example, IBM has pledged several 
hundred patents to the open source community in order to foster innovation. 
201
 
IBM is committed to promoting innovation for the benefit of our customers and for 
the overall growth and advancement of the information technology field. IBM takes 
many actions to promote innovation. Today, we are announcing a new innovation 
initiative. We are pledging the free use of 500 of our U.S. patents, as well as all 
counterparts of these patents issued in other countries, in the development, 
distribution, and use of open source software. We believe that the open source 
community has been at the forefront of innovation and we are taking this action to 
encourage additional innovation for open platforms.
202
 
 
IBM is likely willing to donate patents because those patents are more valuable being used by the 
masses of an open source community than languishing undeveloped by the company.  Future 
value from the use of patented technology by a community can be generated by technological 
advances that IBM can later capitalize on.  There is no reason to think that this perceived future 
value is limited to the context of software.  It is entirely possible that biotechnology companies 
and universities, which hold patents on foundational technologies relevant to synthetic biology, 
would similarly value work done by the open source community of the BioBricks Foundation.   
 But getting patent holders to donate the presently valuable intellectual property rights to 
an open source community will be more challenging.  This is despite the fact that an open-source 
community can also generate future value from technology patents no matter what the present 
value is.
203
  Patent holders may be hesitant to donate their biological parts to the BioBricks 
Foundation via the standard BioBricks Public Agreement because it would prevent enforcement 
of any rights against users.  The terms of the Public Agreement create a risk for an entity that has 
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invested large sums of money in obtaining a patent over valuable sequences of DNA because a 
competitor could theoretically sign its own BioBrick Public Agreement and then be able to 
infringe patent rights with impunity.  By donating a valuable biological part to the BioBrick 
Foundation, a patent holder might inadvertently give up rights to a direct competitor. 
 This problem could possibly be overcome by a direct agreement between the BioBrick 
Foundation and a patent holder, in which it is agreed to allow the use of patented technology by 
members of the BioBrick Foundation, without actually signing the Contributor Agreement.  This, 
however, leaves open the possibility that the patent holder could decide to assert intellectual 
property rights at a later date, stopping all future innovation with the part.  No member of the 
BioBrick Foundation would want to invest time developing a technology only to be told to stop 
at some future date. 
 The establishment of a private standard setting organization would create a medium 
through which the patented biological part could be given to BioBrick members while at the 
same time protecting the intellectual property rights of the donor.   The private SSO would 
include a unique provision to achieve this end.  The SSO contract would contain an ex-ante 
RAND term that creates a sliding scale based on the non-profit or for-profit nature of the entity 
using the patented material.  For the non-profit organization, the reasonable and 
nondiscriminatory license fee would be zero.  For all other organizations joining the private-
SSO, the license terms would follow the fair market value of the patent rights.  Using RAND 
terms of this nature will motivate patent holders of biological parts to donate them to an open 
source community because future value will be generated on the part, and competitors would not 
have the opportunity to exploit a donation.   
 ii. An SSO Addresses Issues of Enforceability Involved with a Licensing Agreement  
 38 
 
 As discussed in Section V above, one of the problems with using a contract licensing 
approach to maintaining openness in the BioBricks Foundation is that the terms can be violated 
by a party without any real recourse.
204
  For example, a donor of a biological part could make a 
promise not to assert any patent rights over a donated part, but then later demand that the part not 
be used.   To remedy this, donation of biological parts under the umbrella of an SSO would make 
it perfectly clear that the agreement is not simply an agreement among parties to use the patented 
material, but rather the adoption of a standard part in which time and money will be invested.  
This clear establishment that a standard is being adopted will bring with it several aspects of 
protection that exist in common law.   
 There is clear case law indicating that, when a patent holder induces another party to 
adopt a standard, the patent holder cannot arbitrarily enforce his or her rights.
205
  One legal 
theory is that of equitable estoppel.  In Stambler v. Diebold, Inc., the plaintiff allowed the 
American National Standards Institute (ANSI) to adopt a technology relating to ATM machines 
as the standard.
206
  The court held that there was evidence of “misleading conduct on the part of 
the plaintiff that may have led the defendant to conclude that plaintiff did not intend to enforce 
his patent” and further that the conduct was intentional.207 The court used a theory of estoppel to 
deny the plaintiff the right to enforce the patent.
208
  The court reasoned that the plaintiff had a 
duty to speak out rather than allow the industry to adopt the standard.
209
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 Furthermore, the Federal Circuit Court of Appeals has articulated a three-part test to 
determine whether a party may use equitable estoppel to bar a patent infringement claim.
210
  The 
court put forward three elements required to invoke equitable estoppel.
211
  First, the patent holder 
must lead the infringer, by misleading conduct, to reasonably infer that no property rights will be 
asserted.
212
  Types of misleading conduct include “specific statements, action, inaction, or 
silence where there was an obligation to speak.”213  Second, the infringer must have relied on the 
misleading conduct of the patent holder.
214
  Third, the infringer will be materially prejudiced by 
allowing proceedings to continue.
215
 
 Applying this three-part test would most likely result in equitable estoppel in the context 
of a biological part donated to the BioBricks Foundation under an SSO.  If a BioBricks part 
Contributor tried to revoke the license of a patent after donating a biological part, all the 
elements of equitable estoppel would be fulfilled.  First, the BioBricks Foundation would have 
reasonably inferred that the Contributor did not enforce the patent because of the acceptance of 
the contributor’s donation. Second, BioBricks would have relied on that agreement by depositing 
the DNA part into the registry.  Third, the BioBrick Foundation would be materially prejudiced 
by enforcement because the foundation would have to, at minimum, spend the time and money 
removing the DNA part from the database. 
 An alternative legal theory preventing the assertion of patent rights over an adopted 
standard is that of an implied license.
216
  Under this theory, future use of the donated biological 
part would not be protected, but damages could not be awarded for use up to the point of 
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notice.
217
   In AMP Incorporated v. The United States, AMP entered into a contract with the 
government to furnish “60 experimental models of [a] wire splicing tool.”218 The contract 
granted the government “an irrevocable, non-exclusive, nontransferable and royalty-free” license 
to use the tool.
219
  After AMP had shipped the items, it discovered that its patent on the tool had 
been infringing another company’s patent.220  AMP purchased the rights to the other companies 
patent and then tried to revoke the original license it granted the government.
221
  The court held 
that an implied license existed between AMP and the government, even though the government 
would have been infringing the third party’s patent.222  The court reasoned that a license cannot 
be negated if there is no change in the structure of the invention.
223
 
 iii.  Enforcing SSO Terms and Bringing Synthetic Biology to the Clinic 
 In the context of a standard setting organization, a scenario is created where proprietary 
entities and open source communities would have an aligned interest in the standard that gets 
adopted.  The patent holder benefits from an increased value of an adopted standard; the parties 
using the patented technology would benefit from enhanced ability to innovate and collaborate 
through use of the standard.  This alignment of interest could significantly benefit the BioBricks 
Foundation because the financial resources of a for-profit corporation might be used to prevent 
any individual member of the SSO from “gaming” the system.224  For example, an SSO member 
that promotes the use of a patented technology, but later tries to enforce patent rights on 
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unreasonable terms, could be sued under one of the legal theories described above.
225
  
Unfortunately, this would require financial resources that the BioBick Foundation does not have 
on its own.  If, however, the interests of the other SSO members were aligned with that of the 
BioBrick Foundation, then a party with money to spend could be present, and would protect the 
interest of the BioBrick Foundation incidentally with its own self-interest.  Thus, the legal 
recourse existing, but practically not possible to use, becomes available to the BioBrick 
Foundation in the context of an SSO. 
 Also, the aligned interests of the BioBrick Foundation with the for-profit members of the 
SSO make it possible to address a problem to establishing a synthetic biology commons that no 
other previously proposed strategy could—that is, get finished, medically relevant, products of 
BioBrick members out of the lab and into the clinic.  For profit biotechnology companies have 
the resources and expertise available to undergo the arduous process of a clinical trial.  Also, 
since clinical trials last many years, the single entity of a corporation could stay focused on 
seeing the process through, without burdening any individual person.  These are things that a 
synthetic biology commons could not achieve by its very nature, with many individuals investing 
little time and money and producing something big with their aggregate work.  Thus, with the 
alignment of interests, the novel biological parts made by BioBrick members could be used 
freely by all for-profit members of the SSO.  These novel biological parts could then be used to 
derive therapies, which can be patented, incentivizing investment into clinical trials.  To keep the 
cycle of innovation going, the for-profit patented technologies could be adopted as standards and 
used further by BioBricks members under the same SSO terms.   
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Conclusion 
 The emerging technology of synthetic biology promises to have a huge impact on 
industry and medicine.
226
  With that in mind, efforts should be made to promote the development 
of the technology in a way that maximizes the speed of innovation.  In the world of 
biotechnology, where patents dominate,
227
 an open source approach to synthetic biology may be 
a good way to drive the technology forward and avoid potential stifling effects of intellectual 
property rights.  This Comment has reviewed some problems associated with an open-source 
approach to synthetic biology and various strategies used in the context of other technologies for 
maintaining openness.  This Comment argues that a patent or copyright approach for maintaining 
openness is not possible and that a license approach is less than ideal.  This Comment proposes a 
novel SSO approach that could not only maintain openness, but also motivate donation of 
synthetic biology parts and help bring biomedical advances closer to clinical trials.  The stated 
goal of the BioBrick Foundation is to “accelerate the pace of innovation, collapse development 
timelines and speed time-to-market of inventive synthetic biology-based solutions.”228  Private 
standard setting organizations have achieved these same ends with various other technologies.
229
 
Thus, even though the BioBrick Foundation strategy for advancing synthetic biology involves 
largely open source principles, the goals of the Foundation may be better advanced by the 
establishment of a formal private standard setting organization.   In a world where sequences of 
DNA are deemed patentable subject matter and intellectual property rights over foundational 
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technologies threaten to stifle progress, creative thinking is necessary in order to advance 
synthetic biology, and unlock the vast potential it has to benefit the world.   
 
  
 
